HopeStage
Back to all studies
CompletedNCT00167310

Omega-3 supplements for heart health in people with serious mental health conditions

About this titleRead the official source — NCT00167310
Medication studyAges 18+United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
PittsburghSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2005
Recruitment status
Completed
Enrollment listed in the registry
57
Sponsor
University of Pittsburgh
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00167310
Official title
Show the full official title

CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Pittsburgh

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Pittsburgh, a university.

Did this study involve medication?

Yes. The study involved medication, including Eicosapentaenoic acid (omega-3 fatty acid) and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies